001     1018541
005     20250204113739.0
024 7 _ |a 10.1007/s11307-023-01861-2
|2 doi
024 7 _ |a 1536-1632
|2 ISSN
024 7 _ |a 1860-2002
|2 ISSN
024 7 _ |a 10.34734/FZJ-2023-04869
|2 datacite_doi
024 7 _ |a 37848641
|2 pmid
024 7 _ |a WOS:001183226500001
|2 WOS
037 _ _ |a FZJ-2023-04869
082 _ _ |a 570
100 1 _ |a Filss, Christian
|0 P:(DE-Juel1)141877
|b 0
|e Corresponding author
|u fzj
245 _ _ |a Assessment of Brain Tumour Perfusion Using Early-Phase 18F-FET PET: Comparison with Perfusion-Weighted MRI
260 _ _ |a Cham
|c 2024
|b Springer Nature Switzerland
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1716354321_24972
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a AbstractPurpose Morphological imaging using MRI is essential for brain tumour diagnostics. Dynamic susceptibility contrast (DSC)perfusion-weighted MRI (PWI), as well as amino acid PET, may provide additional information in ambiguous cases. SincePWI is often unavailable in patients referred for amino acid PET, we explored whether maps of relative cerebral blood volume(rCBV) in brain tumours can be extracted from the early phase of PET using O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET).Procedure Using a hybrid brain PET/MRI scanner, PWI and dynamic 18F-FET PET were performed in 33 patients withcerebral glioma and four patients with highly vascularized meningioma. The time interval from 0 to 2 min p.i. was selectedto best reflect the blood pool phase in 18F-FET PET. For each patient, maps of MR-rCBV, early 18F-FET PET (0–2 min p.i.)and late 18F-FET PET (20–40 min p.i.) were generated and coregistered. Volumes of interest were placed on the tumour(VOI-TU) and normal-appearing brain (VOI-REF). The correlation between tumour-to-brain ratios (TBR) of the differentparameters was analysed. In addition, three independent observers evaluated MR-rCBV and early 18F-FET maps (18F-FETrCBV)for concordance in signal intensity, tumour extent and intratumoural distribution.Results TBRs calculated from MR-rCBV and 18F-FET-rCBV showed a significant correlation (r = 0.89, p < 0.001), whilethere was no correlation between late 18F-FET PET and MR-rCBV (r = 0.24, p = 0.16) and 18F-FET-rCBV (r = 0.27, p =0.11). Visual rating yielded widely agreeing findings or only minor differences between MR-rCBV maps and 18F-FET-rCBVmaps in 93 % of the tumours (range of three independent raters 91–94%, kappa among raters 0.78–1.0).Conclusion Early 18F-FET maps (0–2 min p.i.) in gliomas provide similar information to MR-rCBV maps and may be helpfulwhen PWI is not possible or available. Further studies in gliomas are needed to evaluate whether 18F-FET-rCBV providesthe same clinical information as MR-rCBV.Keywords Brain tumour · Glioma · PWI · rCBV · Early FET PET · Glioma · O-(2-18F-Fluoroethyl)-L-tyrosine · Aminoacid PET
536 _ _ |a 5252 - Brain Dysfunction and Plasticity (POF4-525)
|0 G:(DE-HGF)POF4-5252
|c POF4-525
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de
700 1 _ |a Cramer, Julian
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Löher, Saskia
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Lohmann, Philipp
|0 P:(DE-Juel1)145110
|b 3
|u fzj
700 1 _ |a Stoffels, Gabriele
|0 P:(DE-Juel1)131627
|b 4
|u fzj
700 1 _ |a Stegmayr, Carina
|0 P:(DE-Juel1)156479
|b 5
|u fzj
700 1 _ |a Kocher, Martin
|0 P:(DE-Juel1)173675
|b 6
|u fzj
700 1 _ |a Heinzel, Alexander
|0 P:(DE-Juel1)132315
|b 7
|u fzj
700 1 _ |a Galldiks, Norbert
|0 P:(DE-Juel1)143792
|b 8
|u fzj
700 1 _ |a Wittsack, Hans J.
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Sabel, Michael
|0 P:(DE-Juel1)165921
|b 10
700 1 _ |a Neumaier, Bernd
|0 P:(DE-Juel1)166419
|b 11
|u fzj
700 1 _ |a Scheins, Jürgen
|0 P:(DE-Juel1)131791
|b 12
|u fzj
700 1 _ |a Shah, N. Jon
|0 P:(DE-Juel1)131794
|b 13
|u fzj
700 1 _ |a Meyer, Philipp T.
|0 P:(DE-HGF)0
|b 14
700 1 _ |a Mottaghy, Felix M.
|0 P:(DE-Juel1)132318
|b 15
|u fzj
700 1 _ |a Langen, Karl-Josef
|0 P:(DE-Juel1)131777
|b 16
|u fzj
773 _ _ |a 10.1007/s11307-023-01861-2
|0 PERI:(DE-600)2079211-6
|p 36-44
|t Molecular imaging & biology
|v 26
|y 2024
|x 1536-1632
856 4 _ |u https://juser.fz-juelich.de/record/1018541/files/s11307-023-01861-2.pdf
|y OpenAccess
856 4 _ |u https://juser.fz-juelich.de/record/1018541/files/s11307-023-01861-2.gif?subformat=icon
|x icon
|y OpenAccess
856 4 _ |u https://juser.fz-juelich.de/record/1018541/files/s11307-023-01861-2.jpg?subformat=icon-1440
|x icon-1440
|y OpenAccess
856 4 _ |u https://juser.fz-juelich.de/record/1018541/files/s11307-023-01861-2.jpg?subformat=icon-180
|x icon-180
|y OpenAccess
856 4 _ |u https://juser.fz-juelich.de/record/1018541/files/s11307-023-01861-2.jpg?subformat=icon-640
|x icon-640
|y OpenAccess
909 C O |o oai:juser.fz-juelich.de:1018541
|p openaire
|p open_access
|p OpenAPC_DEAL
|p driver
|p VDB
|p openCost
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 0
|6 P:(DE-Juel1)141877
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 3
|6 P:(DE-Juel1)145110
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 4
|6 P:(DE-Juel1)131627
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 5
|6 P:(DE-Juel1)156479
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 6
|6 P:(DE-Juel1)173675
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 7
|6 P:(DE-Juel1)132315
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 8
|6 P:(DE-Juel1)143792
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 11
|6 P:(DE-Juel1)166419
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 12
|6 P:(DE-Juel1)131791
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 13
|6 P:(DE-Juel1)131794
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 15
|6 P:(DE-Juel1)132318
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 16
|6 P:(DE-Juel1)131777
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5252
|x 0
914 1 _ |y 2024
915 p c |a APC keys set
|0 PC:(DE-HGF)0000
|2 APC
915 p c |a Local Funding
|0 PC:(DE-HGF)0001
|2 APC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-22
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-22
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2023-08-22
|w ger
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-20
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOL IMAGING BIOL : 2022
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-20
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-20
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-20
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 0
920 1 _ |0 I:(DE-Juel1)INM-4-20090406
|k INM-4
|l Physik der Medizinischen Bildgebung
|x 1
920 1 _ |0 I:(DE-Juel1)INM-5-20090406
|k INM-5
|l Nuklearchemie
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 _ _ |a I:(DE-Juel1)INM-4-20090406
980 _ _ |a I:(DE-Juel1)INM-5-20090406
980 _ _ |a APC
980 _ _ |a UNRESTRICTED
980 1 _ |a APC
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21